Stay updated on Cabozantinib in HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.

Latest updates to the Cabozantinib in HR+ Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no changes to study data or core page content.SummaryDifference0.1%

- Check10 days agoChange DetectedGlossary is now shown by default (Show glossary). The labels related to QC criteria and FEAR Act data have standardized capitalization (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision tag updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed, indicating a minor maintenance update to the site. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedDifference0.3%

- Check69 days agoChange DetectedThe page now displays a revision note indicating the site version was updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check76 days agoChange DetectedPublications section now states entries are automatically filled from PubMed and may not relate to the study, and the revision tag was updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib in HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in HR+ Breast Cancer Clinical Trial page.